Windtree Therapeutics Files 8-K on Financials and Delisting Concerns
Ticker: WINTW · Form: 8-K · Filed: Nov 27, 2024 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Nov 27, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, financial-condition, operations
TL;DR
Windtree Therapeutics might get delisted, check financials ASAP.
AI Summary
Windtree Therapeutics, Inc. filed an 8-K on November 21, 2024, reporting on its financial condition and operations. The filing also addresses a notice of delisting or failure to meet continued listing rules, indicating potential issues with the company's stock exchange status.
Why It Matters
This filing is crucial for investors as it signals potential financial distress and the risk of the company's stock being delisted from its exchange.
Risk Assessment
Risk Level: high — The company is filing an 8-K specifically addressing a notice of delisting or failure to satisfy continued listing rules, which is a significant red flag.
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- November 21, 2024 (date) — Date of earliest event reported
FAQ
What specific listing rule has Windtree Therapeutics failed to meet?
The filing indicates a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify which rule has been violated in the provided text.
What are the implications of a potential delisting for Windtree Therapeutics?
A delisting could significantly reduce the liquidity of the company's stock and make it harder for investors to trade shares, potentially impacting its market value.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on November 21, 2024.
What is the primary business of Windtree Therapeutics?
Windtree Therapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code.
Has Windtree Therapeutics undergone any previous name changes?
Yes, Windtree Therapeutics, Inc. was formerly known as Discovery Laboratories Inc. /DE/, Ansan Pharmaceuticals Inc., and Ansan Inc., with name changes occurring in 1997, 1996, and 1995 respectively.
Filing Stats: 702 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-11-27 16:43:38
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital M
Filing Documents
- wint20240909_8k.htm (8-K) — 33KB
- ex_722476.htm (EX-99.1) — 180KB
- logo.jpg (GRAPHIC) — 7KB
- 0001437749-24-036346.txt ( ) — 369KB
- wint-20241121.xsd (EX-101.SCH) — 3KB
- wint-20241121_def.xml (EX-101.DEF) — 11KB
- wint-20241121_lab.xml (EX-101.LAB) — 15KB
- wint-20241121_pre.xml (EX-101.PRE) — 11KB
- wint20240909_8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operations and Financial Condition On November 27, 2024, Windtree Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2024 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing O n November 21, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Form 10-Q") with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the SEC. Based on the November 26, 2024 filing of the Company's Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 99.1 Press Release of Windtree Therapeutics, Inc., dated November 27, 2024 announcing financial results for the quarter ended September 30, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Windtree Therapeutics, Inc. By: /s/ Craig E. Fraser Name: Craig E. Fraser Title: President and Chief Executive Officer Date: November 27, 2024